Welcome to our dedicated page for Cel-Sci Corporation news (Ticker: $CVM), a resource for investors and traders seeking the latest updates and insights on Cel-Sci Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cel-Sci Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cel-Sci Corporation's position in the market.
Rhea-AI Summary
CEL-SCI Corporation (CVM) Announces Closing of $5 Million Public Offering for Cancer Immunotherapy Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced the pricing of an offering of 2,490,000 shares of its common stock at $2.00 per share, generating gross proceeds of approximately $5 million. The net proceeds will be used for the development of Multikine, general corporate purposes, and working capital. The offering is expected to close on November 20, 2023. ThinkEquity is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.57%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation releases a shareholder letter from CEO Geert Kersten, detailing the efficacy of Multikine in head and neck cancer patients and plans for regulatory approval. The letter highlights the well-defined target population, the pre-surgical responses caused by Multikine, and the outstanding survival benefit. CEL-SCI believes they meet the necessary factors for approval and are eager to move forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
Rhea-AI Summary
CEL-SCI Corporation releases video presentation on the impact of recent data on their immunotherapy drug Multikine for the treatment of advanced squamous cell carcinoma of the head and neck.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation has finalized the selection criteria for the head and neck cancer target population to be treated with its immunotherapy drug Multikine. The target population consists of patients with low PD-L1 expression. The data from the Phase 3 trial showed a 28% 5-year absolute survival advantage for Multikine-treated patients compared to the control group. CEL-SCI plans to seek immediate approval for commercial distribution without waiting for completion of a confirmatory study in this target population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.12%
Tags
-
Rhea-AI Summary
CEL-SCI achieves significant milestones towards commissioning of manufacturing facility for Biologics License Application
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
Rhea-AI Summary
CEL-SCI requests approval for Multikine immunotherapy for head and neck cancer treatment in the UK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
-
Rhea-AI Summary
CEL-SCI files request for Scientific Advice with the European Medicines Agency regarding Multikine immunotherapy for head and neck cancer treatment in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the quarter ended June 30, 2023, along with key clinical and corporate developments. Health Canada advised CEL-SCI to request advance consideration for approval under a Notice of Compliance with Conditions (NOCC) policy, potentially leading to commercialization in 2024. Europe is a priority market for CEL-SCI, seeking conditional marketing authorization for Multikine. The FDA acknowledged the need for improved treatments for head and neck cancer, showing potential for close collaboration with CEL-SCI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.68%
Tags
Rhea-AI Summary
CEL-SCI Corporation closes public offering, raising $5 million for cancer immunotherapy development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
Cel-Sci Corporation
NYSE:CVM
CVM Rankings
CVM Stock Data
87.99M
48.49M
3.2%
12.44%
12.69%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
VIENNA
About CVM
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.